APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long Acting Beta 2 Agonist

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Long Acting Beta 2 Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025188 pages

Choose your research edition.

Industry ResearchLong Acting Beta 2 Agonist Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Long Acting Beta 2 Agonist Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Long Acting Beta 2 Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long Acting Beta 2 Agonist Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Long Acting Beta 2 Agonist Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Long Acting Beta 2 Agonist market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Long Acting Beta 2 Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long Acting Beta 2 Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long Acting Beta 2 Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Long Acting Beta 2 Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Long Acting Beta 2 Agonist include GSK, Teva, Novartis, Chiesi, AstraZeneca, Organon and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Long Acting Beta 2 Agonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long Acting Beta 2 Agonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long Acting Beta 2 Agonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long Acting Beta 2 Agonist market size, projected growth trends, production technologies, key applications, and end-use industries.

Long Acting Beta 2 Agonist Segment by Company

GSK

Teva

Novartis

Chiesi

AstraZeneca

Organon

Boehringer Ingelheim

Long Acting Beta 2 Agonist Segment by Type

Serevent

Foradil

Other

Long Acting Beta 2 Agonist Segment by Application

COPD

Asthma

Other

Long Acting Beta 2 Agonist Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long Acting Beta 2 Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long Acting Beta 2 Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long Acting Beta 2 Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long Acting Beta 2 Agonist market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Long Acting Beta 2 Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Long Acting Beta 2 Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Long Acting Beta 2 Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Long Acting Beta 2 Agonist Industry Trends Table 2. Long Acting Beta 2 Agonist Industry Drivers Table 3. Long Acting Beta 2 Agonist Industry Opportunities and Challenges Table 4. Long Acting Beta 2 Agonist Industry Restraints Table 5. Global Long Acting Beta 2 Agonist Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Long Acting Beta 2 Agonist Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Long Acting Beta 2 Agonist Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Long Acting Beta 2 Agonist Sales Market Share by Manufacturers Table 9. Global Long Acting Beta 2 Agonist Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Long Acting Beta 2 Agonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Long Acting Beta 2 Agonist Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Long Acting Beta 2 Agonist Manufacturers, Product Type & Application Table 13. Global Long Acting Beta 2 Agonist Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Long Acting Beta 2 Agonist by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Serevent Table 17. Major Manufacturers of Foradil Table 18. Major Manufacturers of Other Table 19. Global Long Acting Beta 2 Agonist Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Long Acting Beta 2 Agonist Sales by Type (2021-2026) & (k units) Table 21. Global Long Acting Beta 2 Agonist Sales by Type (2027-2032) & (k units) Table 22. Global Long Acting Beta 2 Agonist Sales Market Share by Type (2021-2026) Table 23. Global Long Acting Beta 2 Agonist Sales Market Share by Type (2027-2032) Table 24. Global Long Acting Beta 2 Agonist Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Long Acting Beta 2 Agonist Revenue by Type (2021-2026) & (k units) Table 26. Global Long Acting Beta 2 Agonist Revenue by Type (2027-2032) & (k units) Table 27. Global Long Acting Beta 2 Agonist Revenue Market Share by Type (2021-2026) Table 28. Global Long Acting Beta 2 Agonist Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of COPD Table 30. Major Manufacturers of Asthma Table 31. Major Manufacturers of Other Table 32. Global Long Acting Beta 2 Agonist Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Long Acting Beta 2 Agonist Sales by Application (2021-2026) & (k units) Table 34. Global Long Acting Beta 2 Agonist Sales by Application (2027-2032) & (k units) Table 35. Global Long Acting Beta 2 Agonist Sales Market Share by Application (2021-2026) Table 36. Global Long Acting Beta 2 Agonist Sales Market Share by Application (2027-2032) Table 37. Global Long Acting Beta 2 Agonist Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Long Acting Beta 2 Agonist Revenue by Application (2021-2026) & (k units) Table 39. Global Long Acting Beta 2 Agonist Revenue by Application (2027-2032) & (k units) Table 40. Global Long Acting Beta 2 Agonist Revenue Market Share by Application (2021-2026) Table 41. Global Long Acting Beta 2 Agonist Revenue Market Share by Application (2027-2032) Table 42. Global Long Acting Beta 2 Agonist Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Long Acting Beta 2 Agonist Sales by Region (2021-2026) & (k units) Table 44. Global Long Acting Beta 2 Agonist Sales Market Share by Region (2021-2026) Table 45. Global Long Acting Beta 2 Agonist Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Long Acting Beta 2 Agonist Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Long Acting Beta 2 Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Long Acting Beta 2 Agonist Sales by Country (2021-2026) & (k units) Table 49. North America Long Acting Beta 2 Agonist Sales by Country (2027-2032) & (k units) Table 50. Europe Long Acting Beta 2 Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Long Acting Beta 2 Agonist Sales by Country (2021-2026) & (k units) Table 52. Europe Long Acting Beta 2 Agonist Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Long Acting Beta 2 Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Long Acting Beta 2 Agonist Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Long Acting Beta 2 Agonist Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Long Acting Beta 2 Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Long Acting Beta 2 Agonist Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Long Acting Beta 2 Agonist Sales by Country (2027-2032) & (k units) Table 59. Global Long Acting Beta 2 Agonist Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Long Acting Beta 2 Agonist Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Long Acting Beta 2 Agonist Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Long Acting Beta 2 Agonist Revenue Market Share by Region (2021-2026) Table 63. Global Long Acting Beta 2 Agonist Revenue Market Share by Region (2027-2032) Table 64. GSK Company Information Table 65. GSK Business Overview Table 66. GSK Long Acting Beta 2 Agonist Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. GSK Long Acting Beta 2 Agonist Product Portfolio Table 68. GSK Recent Development Table 69. Teva Company Information Table 70. Teva Business Overview Table 71. Teva Long Acting Beta 2 Agonist Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Teva Long Acting Beta 2 Agonist Product Portfolio Table 73. Teva Recent Development Table 74. Novartis Company Information Table 75. Novartis Business Overview Table 76. Novartis Long Acting Beta 2 Agonist Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Novartis Long Acting Beta 2 Agonist Product Portfolio Table 78. Novartis Recent Development Table 79. Chiesi Company Information Table 80. Chiesi Business Overview Table 81. Chiesi Long Acting Beta 2 Agonist Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Chiesi Long Acting Beta 2 Agonist Product Portfolio Table 83. Chiesi Recent Development Table 84. AstraZeneca Company Information Table 85. AstraZeneca Business Overview Table 86. AstraZeneca Long Acting Beta 2 Agonist Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. AstraZeneca Long Acting Beta 2 Agonist Product Portfolio Table 88. AstraZeneca Recent Development Table 89. Organon Company Information Table 90. Organon Business Overview Table 91. Organon Long Acting Beta 2 Agonist Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Organon Long Acting Beta 2 Agonist Product Portfolio Table 93. Organon Recent Development Table 94. Boehringer Ingelheim Company Information Table 95. Boehringer Ingelheim Business Overview Table 96. Boehringer Ingelheim Long Acting Beta 2 Agonist Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Boehringer Ingelheim Long Acting Beta 2 Agonist Product Portfolio Table 98. Boehringer Ingelheim Recent Development Table 99. Key Raw Materials Table 100. Raw Materials Key Suppliers Table 101. Long Acting Beta 2 Agonist Distributors List Table 102. Long Acting Beta 2 Agonist Customers List Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Long Acting Beta 2 Agonist Product Image Figure 2. Global Long Acting Beta 2 Agonist Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long Acting Beta 2 Agonist Market Size (2021-2032) & (US$ Million) Figure 4. Global Long Acting Beta 2 Agonist Sales (2021-2032) & (k units) Figure 5. Global Long Acting Beta 2 Agonist Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Long Acting Beta 2 Agonist Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Serevent Image Figure 9. Foradil Image Figure 10. Other Image Figure 11. Global Long Acting Beta 2 Agonist Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Long Acting Beta 2 Agonist Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Long Acting Beta 2 Agonist Sales Market Share by Type (2021-2032) Figure 14. Global Long Acting Beta 2 Agonist Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Long Acting Beta 2 Agonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Long Acting Beta 2 Agonist Revenue Market Share by Type (2021-2032) Figure 17. COPD Image Figure 18. Asthma Image Figure 19. Other Image Figure 20. Global Long Acting Beta 2 Agonist Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Long Acting Beta 2 Agonist Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Long Acting Beta 2 Agonist Sales Market Share by Application (2021-2032) Figure 23. Global Long Acting Beta 2 Agonist Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Long Acting Beta 2 Agonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Long Acting Beta 2 Agonist Revenue Market Share by Application (2021-2032) Figure 26. North America Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Long Acting Beta 2 Agonist Sales Market Share by Country (2021-2032) Figure 28. U.S. Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Long Acting Beta 2 Agonist Sales Market Share by Country (2021-2032) Figure 33. Germany Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Long Acting Beta 2 Agonist Sales Market Share by Country (2021-2032) Figure 40. China Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Long Acting Beta 2 Agonist Sales Market Share by Country (2021-2032) Figure 48. Brazil Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Long Acting Beta 2 Agonist Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Long Acting Beta 2 Agonist Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Long Acting Beta 2 Agonist Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Long Acting Beta 2 Agonist Revenue (2021-2032) & (US$ Million) Figure 59. North America Long Acting Beta 2 Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Long Acting Beta 2 Agonist Revenue (2021-2032) & (US$ Million) Figure 61. Europe Long Acting Beta 2 Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Long Acting Beta 2 Agonist Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Long Acting Beta 2 Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Long Acting Beta 2 Agonist Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Long Acting Beta 2 Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Long Acting Beta 2 Agonist Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Long Acting Beta 2 Agonist Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Serevent
  • Foradil
  • Other
Applications
  • COPD
  • Asthma
  • Other
Companies covered
  • GSK
  • Teva
  • Novartis
  • Chiesi
  • AstraZeneca
  • Organon
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Long Acting Beta 2 Agonist Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Long Acting Beta 2 Agonist Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Long Acting Beta 2 Agonist Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Long Acting Beta 2 Agonist Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Long Acting Beta 2 Agonist Market Dynamics
  1. 2.1 Long Acting Beta 2 Agonist Industry Trends
  2. 2.2 Long Acting Beta 2 Agonist Industry Drivers
  3. 2.3 Long Acting Beta 2 Agonist Industry Opportunities and Challenges
  4. 2.4 Long Acting Beta 2 Agonist Industry Restraints
3 Long Acting Beta 2 Agonist Market by Manufacturers
  1. 3.1 Global Long Acting Beta 2 Agonist Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Long Acting Beta 2 Agonist Sales by Manufacturers (2021-2026)
  3. 3.3 Global Long Acting Beta 2 Agonist Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Long Acting Beta 2 Agonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Long Acting Beta 2 Agonist Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Long Acting Beta 2 Agonist Manufacturers, Product Type & Application
  7. 3.7 Global Long Acting Beta 2 Agonist Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Long Acting Beta 2 Agonist Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Long Acting Beta 2 Agonist Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Long Acting Beta 2 Agonist Tier 1, Tier 2, and Tier 3
4 Long Acting Beta 2 Agonist Market by Type
  1. 4.1 Long Acting Beta 2 Agonist Type Introduction
  2. 4.1.1 Serevent
  3. 4.1.2 Foradil
  4. 4.1.3 Other
  5. 4.2 Global Long Acting Beta 2 Agonist Sales by Type
  6. 4.2.1 Global Long Acting Beta 2 Agonist Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Long Acting Beta 2 Agonist Sales by Type (2021-2032)
  8. 4.2.3 Global Long Acting Beta 2 Agonist Sales Market Share by Type (2021-2032)
  9. 4.3 Global Long Acting Beta 2 Agonist Revenue by Type
  10. 4.3.1 Global Long Acting Beta 2 Agonist Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Long Acting Beta 2 Agonist Revenue by Type (2021-2032)
  12. 4.3.3 Global Long Acting Beta 2 Agonist Revenue Market Share by Type (2021-2032)
5 Long Acting Beta 2 Agonist Market by Application
  1. 5.1 Long Acting Beta 2 Agonist Application Introduction
  2. 5.1.1 COPD
  3. 5.1.2 Asthma
  4. 5.1.3 Other
  5. 5.2 Global Long Acting Beta 2 Agonist Sales by Application
  6. 5.2.1 Global Long Acting Beta 2 Agonist Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long Acting Beta 2 Agonist Sales by Application (2021-2032)
  8. 5.2.3 Global Long Acting Beta 2 Agonist Sales Market Share by Application (2021-2032)
  9. 5.3 Global Long Acting Beta 2 Agonist Revenue by Application
  10. 5.3.1 Global Long Acting Beta 2 Agonist Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Long Acting Beta 2 Agonist Revenue by Application (2021-2032)
  12. 5.3.3 Global Long Acting Beta 2 Agonist Revenue Market Share by Application (2021-2032)
6 Global Long Acting Beta 2 Agonist Sales by Region
  1. 6.1 Global Long Acting Beta 2 Agonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long Acting Beta 2 Agonist Sales by Region (2021-2032)
  3. 6.2.1 Global Long Acting Beta 2 Agonist Sales by Region (2021-2026)
  4. 6.2.2 Global Long Acting Beta 2 Agonist Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Long Acting Beta 2 Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Long Acting Beta 2 Agonist Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Long Acting Beta 2 Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Long Acting Beta 2 Agonist Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Long Acting Beta 2 Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Long Acting Beta 2 Agonist Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Long Acting Beta 2 Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Long Acting Beta 2 Agonist Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Long Acting Beta 2 Agonist Revenue by Region
  1. 7.1 Global Long Acting Beta 2 Agonist Revenue by Region
  2. 7.1.1 Global Long Acting Beta 2 Agonist Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Long Acting Beta 2 Agonist Revenue by Region (2021-2026)
  4. 7.1.3 Global Long Acting Beta 2 Agonist Revenue by Region (2027-2032)
  5. 7.1.4 Global Long Acting Beta 2 Agonist Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Long Acting Beta 2 Agonist Revenue (2021-2032)
  8. 7.2.2 North America Long Acting Beta 2 Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Long Acting Beta 2 Agonist Revenue (2021-2032)
  11. 7.3.2 Europe Long Acting Beta 2 Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Long Acting Beta 2 Agonist Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Long Acting Beta 2 Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Long Acting Beta 2 Agonist Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Long Acting Beta 2 Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Long Acting Beta 2 Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Long Acting Beta 2 Agonist Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Long Acting Beta 2 Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Long Acting Beta 2 Agonist Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Long Acting Beta 2 Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Long Acting Beta 2 Agonist Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Chiesi
  20. 8.4.1 Chiesi Company Information
  21. 8.4.2 Chiesi Business Overview
  22. 8.4.3 Chiesi Long Acting Beta 2 Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Chiesi Long Acting Beta 2 Agonist Product Portfolio
  24. 8.4.5 Chiesi Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Long Acting Beta 2 Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Long Acting Beta 2 Agonist Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Organon
  32. 8.6.1 Organon Company Information
  33. 8.6.2 Organon Business Overview
  34. 8.6.3 Organon Long Acting Beta 2 Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Organon Long Acting Beta 2 Agonist Product Portfolio
  36. 8.6.5 Organon Recent Developments
  37. 8.7 Boehringer Ingelheim
  38. 8.7.1 Boehringer Ingelheim Company Information
  39. 8.7.2 Boehringer Ingelheim Business Overview
  40. 8.7.3 Boehringer Ingelheim Long Acting Beta 2 Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Boehringer Ingelheim Long Acting Beta 2 Agonist Product Portfolio
  42. 8.7.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Long Acting Beta 2 Agonist Value Chain Analysis
  2. 9.1.1 Long Acting Beta 2 Agonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Long Acting Beta 2 Agonist Production Mode & Process
  6. 9.2 Long Acting Beta 2 Agonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Long Acting Beta 2 Agonist Distributors
  9. 9.2.3 Long Acting Beta 2 Agonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst